Recursion
What they do & why Kinnevik is invested
Recursion integrates advanced AI with machine learning, creating a sector-defining company in drug discovery and development. Its strategy rests on three core pillars:
- Developing an extensive in-house pipeline, where Recursion bears all R&D costs and retains full upside from successful drugs
- Co-development partnerships with industry leaders such as Roche and Genentech, Sanofi, and Bayer
- Building industry-leading biological and chemical proprietary datasets via wet lab automation and partnerships – now 65 petabytes and growing – to drive new insights in "difficult to treat" diseases
Last year, Recursion joined forces with Exscientia, another leading AI drug discovery company, combining two of the most advanced platforms in the field and significantly expanding its pipeline and capabilities in precision chemistry.
Kinnevik views Recursion as the leading AI-native drug discovery and development company. Its strong capital base, proven execution and ability to scale its platform across both internal and partnered pipelines position it to capture multi-billion-dollar milestone payments in the years ahead.
Of note is its multi-year collaboration with NVIDIA – a groundbreaking effort to build foundational models in biology and chemistry, using the most powerful private supercomputer in the pharma industry.
Key information
- Clinical-stage techbio company decoding biology to industrialize drug discovery and design novel therapeutics, delivering on average 3x the speed to clinical at half the cost of traditional pharma
- Enabled by its integrated AI-enabled full stack platform that continuously expands one of the world’s largest proprietary biological and chemical datasets
News in the quarter
- Acquired full rights to an inhibitor program for the treatment of hypophosphatasia, developed in partnership with Rallybio, enabling Recursion to accelerate the development of the first potential oral disease-modifying treatment for patients with hypophosphatasia
- Advanced platform with launch of Boltz-2, a next-generation AI model for molecular interaction prediction, developed in collaboration with MIT’s CSAIL and Jameel Clinic
